Gamze Vuran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gamze Vuran has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Timur Meşe
Department of Pediatric Cardiology, University of Health Sciences, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Türkiye
8 shared publications - Murat Muhtar Yılmazer
Department of Pediatric Cardiology, Izmir Dr. Behcet Uz Children’s Hospital, Alsancak, Izmir, Turkey
5 shared publications Murat Muhtar Yılmazer
Department of Pediatric Cardiology, University of Health Sciences, İzmir Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Turkey
4 shared publications- Mustafa Mertkan Bilen
Department of Pediatric Cardiology, University of Health Sciences, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Türkiye
4 shared publications - Cem Doğan
Department of Pediatric Cardiology, University of Health Sciences, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Türkiye
3 shared publications - Cüneyt Zihni
Department of Pediatric Cardiology, University of Health Sciences, İzmir Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, İzmir, Turkey
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-8
PEDIATRIC PERICARDIAL EFFUSION REQUIRING INVASIVE INTERVENTION: A 13-YEAR SINGLE-CENTER EXPERIENCE
Objective: Moderate-to-large pericardial effusion in children is a potentially life-threatening condition that requires prompt diagnosis and timely intervention. However, data focusing specifically on children requiring invasive management remain limited. This study aimed to evaluate the etiological spectrum, clinical characteristics, management, and outcomes of children undergoing invasive intervention for moderate-to-large pericardial effusion. Methods: This retrospective single-center study included children (0–18 years) who underwent pericardiocentesis or surgical drainage for moderate-to-large pericardial effusion between January 2012 and December 2024. Demographic, clinical, laboratory, echocardiographic, procedural, and outcome data were reviewed. Results: Thirty-eight children underwent invasive intervention during the 13-year study period. Infectious diseases were the most common etiology (36.8%), followed by idiopathic, rheumatologic, and malignant causes. Respiratory symptoms were the predominant presenting manifestation (68.4%), and cardiac tamponade was present in 31.6% of patients. Pericardiocentesis was the initial treatment in 30 patients, of whom 15 (50.0%) required no further invasive intervention, while 19 (63.3%) did not require surgical drainage. Eleven patients (36.7%) ultimately required surgical drainage during follow-up. Procedure-related complications were uncommon; hemopericardium requiring emergency surgery occurred in two patients (5.3%). In-hospital mortality was 13.2% and was attributable to severe underlying diseases rather than procedural complications. Conclusion: Infectious diseases remain the leading cause of clinically significant pediatric pericardial effusion requiring invasive intervention. Echocardiography-guided pericardiocentesis is an effective initial treatment for most patients; however, recurrent, loculated, or complex effusions frequently require surgical management. Early recognition, accurate etiological diagnosis, and individualized multidisciplinary management are essential to optimize outcomes in children requiring invasive treatment.
- 26 October 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-8
Open AccessPEDIATRIC PERICARDIAL EFFUSION REQUIRING INVASIVE INTERVENTION: A 13-YEAR SINGLE-CENTER EXPERIENCE
Objective: Moderate-to-large pericardial effusion in children is a potentially life-threatening condition that requires prompt diagnosis and timely intervention. However, data focusing specifically on children requiring invasive management remain limited. This study aimed to evaluate the etiological spectrum, clinical characteristics, management, and outcomes of children undergoing invasive intervention for moderate-to-large pericardial effusion. Methods: This retrospective single-center study included children (0–18 years) who underwent pericardiocentesis or surgical drainage for moderate-to-large pericardial effusion between January 2012 and December 2024. Demographic, clinical, laboratory, echocardiographic, procedural, and outcome data were reviewed. Results: Thirty-eight children underwent invasive intervention during the 13-year study period. Infectious diseases were the most common etiology (36.8%), followed by idiopathic, rheumatologic, and malignant causes. Respiratory symptoms were the predominant presenting manifestation (68.4%), and cardiac tamponade was present in 31.6% of patients. Pericardiocentesis was the initial treatment in 30 patients, of whom 15 (50.0%) required no further invasive intervention, while 19 (63.3%) did not require surgical drainage. Eleven patients (36.7%) ultimately required surgical drainage during follow-up. Procedure-related complications were uncommon; hemopericardium requiring emergency surgery occurred in two patients (5.3%). In-hospital mortality was 13.2% and was attributable to severe underlying diseases rather than procedural complications. Conclusion: Infectious diseases remain the leading cause of clinically significant pediatric pericardial effusion requiring invasive intervention. Echocardiography-guided pericardiocentesis is an effective initial treatment for most patients; however, recurrent, loculated, or complex effusions frequently require surgical management. Early recognition, accurate etiological diagnosis, and individualized multidisciplinary management are essential to optimize outcomes in children requiring invasive treatment.
- 15 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 667
Extracriteria manifestations in Kawasaki disease: coronary threat or diagnostic pitfall?
- 15 August 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (9) , 667
Extracriteria manifestations in Kawasaki disease: coronary threat or diagnostic pitfall?
- Open Access
- 1 August 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1716-1718
A rare late presentation of restrictive cor triatriatum sinister in a 14-year-old male mimicking refractory asthma
Cor triatriatum sinister is an exceptionally rare congenital cardiac anomaly [1]. While restrictive forms are typically present in infancy or early childhood, survival into adolescence with a 2–3 mm fenestration is unusual [2, 3]. We report a 14-year-old male, misdiagnosed with refractory asthma for years, who presented with palpitations. Imaging and catheterisation revealed severe post-capillary pulmonary hypertension with echocardiographic evidence of right-sided chamber dilatation, D-shaped left ventricular configuration, moderate tricuspid regurgitation, and an estimated pulmonary artery pressure of 85 mmHg. Cardiac catheterisation showed PA pressure of 50/30 mmHg (mean 39 mmHg), PCWP of 28 mmHg, Qp/Qs of 1.14, and a favourable PVR/SVR ratio of 0.12, indicating reversibility. Successful surgical resection of a calcified membrane was performed via right anterolateral thoracotomy. This case underscores the importance of considering cor triatriatum sinister in adolescents with unexplained respiratory symptoms or wheezing and highlights the value of correlating echocardiographic evidence of obstruction with invasive haemodynamic assessment before surgery [4, 5].
- 1 August 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1716-1718
Open AccessA rare late presentation of restrictive cor triatriatum sinister in a 14-year-old male mimicking refractory asthma
Cor triatriatum sinister is an exceptionally rare congenital cardiac anomaly [1]. While restrictive forms are typically present in infancy or early childhood, survival into adolescence with a 2–3 mm fenestration is unusual [2, 3]. We report a 14-year-old male, misdiagnosed with refractory asthma for years, who presented with palpitations. Imaging and catheterisation revealed severe post-capillary pulmonary hypertension with echocardiographic evidence of right-sided chamber dilatation, D-shaped left ventricular configuration, moderate tricuspid regurgitation, and an estimated pulmonary artery pressure of 85 mmHg. Cardiac catheterisation showed PA pressure of 50/30 mmHg (mean 39 mmHg), PCWP of 28 mmHg, Qp/Qs of 1.14, and a favourable PVR/SVR ratio of 0.12, indicating reversibility. Successful surgical resection of a calcified membrane was performed via right anterolateral thoracotomy. This case underscores the importance of considering cor triatriatum sinister in adolescents with unexplained respiratory symptoms or wheezing and highlights the value of correlating echocardiographic evidence of obstruction with invasive haemodynamic assessment before surgery [4, 5].
- Open Access
- 1 June 2026
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 78 (1)
Transcatheter ventricular septal defect closure in children: ten-year experience with multiple devices and long-term outcomes
Background: Transcatheter closure has become a widely accepted alternative to surgery for VSD, but long-term pediatric data are limited. This study evaluated procedural success, complications, and long-term outcomes with different occluders. Methods: We retrospectively analyzed 118 children who underwent attempted transcatheter VSD closure between 2014 and 2024, with clinical, echocardiographic, and electrocardiographic follow-up. Results: Closure was successful in 110 patients (93%). Failures were due to multifenestrated anatomy, embolization, residual shunt, atrioventricular (AV) block, tricuspid regurgitation, or insufficient aortic rim. Major complications occurred in six patients, including device embolization, progressive aortic regurgitation requiring surgery, persistent nodal rhythm requiring device removal, ventricular perforation, infective endocarditis, and subarachnoid hemorrhage. Minor complications included mild to moderate tricuspid regurgitation (n = 4) and mild aortic regurgitation (n = 5). Arrhythmic events comprised supraventricular tachycardia (n = 2, both resolved), nodal rhythm (n = 1, transient), right bundle branch block (n = 5, persistent in four), and left bundle branch block (n = 1, resolved). Residual shunt was present in 36.4% immediately, declining to 9.8% at follow-up. Larger VSD diameter (OR 1.75, 95% CI 1.14–2.69) and higher body weight (OR 1.07, 95% CI 1.00–1.15) were independent predictors. No late complete AV block, endocarditis, or embolization occurred. Patients treated with Konar-MF were younger and lighter, while Nit-Occlud was associated with higher residual shunt rates (85.7% vs. 33.0%, p = 0.010). Conclusion: Transcatheter VSD closure in children demonstrated high success, acceptable complication rates, and favorable long-term outcomes. Results were influenced by device choice, defect size, and patient characteristics, highlighting the need for individualized strategies and continued surveillance.
- 1 June 2026
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 78 (1)
Open AccessTranscatheter ventricular septal defect closure in children: ten-year experience with multiple devices and long-term outcomes
Background: Transcatheter closure has become a widely accepted alternative to surgery for VSD, but long-term pediatric data are limited. This study evaluated procedural success, complications, and long-term outcomes with different occluders. Methods: We retrospectively analyzed 118 children who underwent attempted transcatheter VSD closure between 2014 and 2024, with clinical, echocardiographic, and electrocardiographic follow-up. Results: Closure was successful in 110 patients (93%). Failures were due to multifenestrated anatomy, embolization, residual shunt, atrioventricular (AV) block, tricuspid regurgitation, or insufficient aortic rim. Major complications occurred in six patients, including device embolization, progressive aortic regurgitation requiring surgery, persistent nodal rhythm requiring device removal, ventricular perforation, infective endocarditis, and subarachnoid hemorrhage. Minor complications included mild to moderate tricuspid regurgitation (n = 4) and mild aortic regurgitation (n = 5). Arrhythmic events comprised supraventricular tachycardia (n = 2, both resolved), nodal rhythm (n = 1, transient), right bundle branch block (n = 5, persistent in four), and left bundle branch block (n = 1, resolved). Residual shunt was present in 36.4% immediately, declining to 9.8% at follow-up. Larger VSD diameter (OR 1.75, 95% CI 1.14–2.69) and higher body weight (OR 1.07, 95% CI 1.00–1.15) were independent predictors. No late complete AV block, endocarditis, or embolization occurred. Patients treated with Konar-MF were younger and lighter, while Nit-Occlud was associated with higher residual shunt rates (85.7% vs. 33.0%, p = 0.010). Conclusion: Transcatheter VSD closure in children demonstrated high success, acceptable complication rates, and favorable long-term outcomes. Results were influenced by device choice, defect size, and patient characteristics, highlighting the need for individualized strategies and continued surveillance.
- Open Access
- 1 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 301-311
Optimized retrograde approach and device selection with Konar-MF™ for pediatric transcatheter ventricular septal defect closure
Background: This study aims to evaluate the mid-term outcomes of transcatheter ventricular septal defect closure with the Konar-MF™ device and to investigate the impact of an optimized device selection strategy using a retrograde approach. Methods: Between January 2019 and November 2023, a total of 58 patients (32 males, 26 females; median age: 4.5 years; range, 8 months to 16 years) who underwent transcatheter closure of ventricular septal defects using the Konar-MF™ device were retrospectively analyzed. Patient demographics, procedural details, and follow-up data were recorded. Results: Procedural success was achieved in 95% of cases, with a median procedure time of 60 min and fluoroscopy time of 12.6 min. Retrograde implantation was used in 79% of patients, significantly reducing procedural time and minimizing complications associated with an arteriovenous loop. Our refined strategy of selecting smaller devices when anatomically feasible played a crucial role in reducing interference with surrounding cardiac structures, substantially contributing to the absence of complete atrioventricular block in our cohort. Major complications included device embolization, moderate aortic regurgitation due to device dislocation, and right ventricular perforation (each in 1.8% of patients). The median follow-up was 34.5 months. Residual shunt rates were initially 42% on postoperative Day 1, reducing to 1.8% by the end of the follow-up period. Conclusion: The Konar-MF™ occluder demonstrated high procedural success and acceptable complication rates for perimembranous ventricular septal defect closure. The use of a retrograde approach and a refined device selection strategy were key factors in achieving favorable outcomes, minimizing complications such as atrioventricular block and valve interference. The device offers significant advantages, making it a suitable alternative to surgical ventricular septal defect closure.
- 1 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 301-311
Open AccessOptimized retrograde approach and device selection with Konar-MF™ for pediatric transcatheter ventricular septal defect closure
Background: This study aims to evaluate the mid-term outcomes of transcatheter ventricular septal defect closure with the Konar-MF™ device and to investigate the impact of an optimized device selection strategy using a retrograde approach. Methods: Between January 2019 and November 2023, a total of 58 patients (32 males, 26 females; median age: 4.5 years; range, 8 months to 16 years) who underwent transcatheter closure of ventricular septal defects using the Konar-MF™ device were retrospectively analyzed. Patient demographics, procedural details, and follow-up data were recorded. Results: Procedural success was achieved in 95% of cases, with a median procedure time of 60 min and fluoroscopy time of 12.6 min. Retrograde implantation was used in 79% of patients, significantly reducing procedural time and minimizing complications associated with an arteriovenous loop. Our refined strategy of selecting smaller devices when anatomically feasible played a crucial role in reducing interference with surrounding cardiac structures, substantially contributing to the absence of complete atrioventricular block in our cohort. Major complications included device embolization, moderate aortic regurgitation due to device dislocation, and right ventricular perforation (each in 1.8% of patients). The median follow-up was 34.5 months. Residual shunt rates were initially 42% on postoperative Day 1, reducing to 1.8% by the end of the follow-up period. Conclusion: The Konar-MF™ occluder demonstrated high procedural success and acceptable complication rates for perimembranous ventricular septal defect closure. The use of a retrograde approach and a refined device selection strategy were key factors in achieving favorable outcomes, minimizing complications such as atrioventricular block and valve interference. The device offers significant advantages, making it a suitable alternative to surgical ventricular septal defect closure.
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (2) , 131-132
Reply to Letter to the Editor: “The Increase in Pediatric Postural Orthostatic Tachycardia Syndrome During the Pandemic May be due to Autonomic Neuropathy as a Complication of SARS-CoV-2 Infection”
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (2) , 131-132
Open AccessReply to Letter to the Editor: “The Increase in Pediatric Postural Orthostatic Tachycardia Syndrome During the Pandemic May be due to Autonomic Neuropathy as a Complication of SARS-CoV-2 Infection”
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (11) , 641-645
Increased Diagnosis Rates and Clinical Characteristics of Pediatric Postural Orthostatic Tachycardia Syndrome During the Coronavirus Disease 2019 Pandemic
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (11) , 641-645
Open AccessIncreased Diagnosis Rates and Clinical Characteristics of Pediatric Postural Orthostatic Tachycardia Syndrome During the Coronavirus Disease 2019 Pandemic
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 6 March 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (7) , 1471-1475
Leukotriene B4 levels in CHD-associated paediatric pulmonary hypertension
Background: The aim of this study is to evaluate the role of leukotriene B4, an inflammatory mediator, in the development of pulmonary hypertension in paediatric patients with CHD with left-right shunt.Methods: The study included forty patients with CHD with left-right shunts. Based on haemodynamic data obtained from cardiac diagnostic catheterisation, 25 patients who met the criteria for pulmonary arterial hypertension were included in the patient group. The control group comprised 15 patients who did not meet the criteria. The standard cardiac haemodynamic study was conducted. Leukotriene B4 levels were assessed in blood samples taken from both pulmonary arteries and peripheral veins.Results: The median age of patients with pulmonary arterial hypertension was 10 months (range: 3–168), while the median age of the control group was 50 months (range: 3–194). In the pulmonary hypertension group, the median pulmonary artery systolic/diastolic/mean pressures were 38/18/24 mmHg, compared to 26/10/18 mmHg in the control group. Leukotriene B4 levels in pulmonary artery blood samples were significantly higher in the pulmonary arterial hypertension group compared to the controls (p < 0.05). Peripheral leukotriene B4 levels were also elevated in the pulmonary arterial hypertension group in comparison to the control group, though the difference was not statistically significant.Conclusion: The discovery of elevated leukotriene B4 levels in pulmonary artery samples from paediatric patients with pulmonary arterial hypertension secondary to CHD with left-to-right shunt suggests that local inflammation may have a pathological role in the development of pulmonary arterial hypertension.
- 6 March 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (7) , 1471-1475
Leukotriene B4 levels in CHD-associated paediatric pulmonary hypertension
Background: The aim of this study is to evaluate the role of leukotriene B4, an inflammatory mediator, in the development of pulmonary hypertension in paediatric patients with CHD with left-right shunt.Methods: The study included forty patients with CHD with left-right shunts. Based on haemodynamic data obtained from cardiac diagnostic catheterisation, 25 patients who met the criteria for pulmonary arterial hypertension were included in the patient group. The control group comprised 15 patients who did not meet the criteria. The standard cardiac haemodynamic study was conducted. Leukotriene B4 levels were assessed in blood samples taken from both pulmonary arteries and peripheral veins.Results: The median age of patients with pulmonary arterial hypertension was 10 months (range: 3–168), while the median age of the control group was 50 months (range: 3–194). In the pulmonary hypertension group, the median pulmonary artery systolic/diastolic/mean pressures were 38/18/24 mmHg, compared to 26/10/18 mmHg in the control group. Leukotriene B4 levels in pulmonary artery blood samples were significantly higher in the pulmonary arterial hypertension group compared to the controls (p < 0.05). Peripheral leukotriene B4 levels were also elevated in the pulmonary arterial hypertension group in comparison to the control group, though the difference was not statistically significant.Conclusion: The discovery of elevated leukotriene B4 levels in pulmonary artery samples from paediatric patients with pulmonary arterial hypertension secondary to CHD with left-to-right shunt suggests that local inflammation may have a pathological role in the development of pulmonary arterial hypertension.
- Open Access
- 28 November 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (12) , 864-871
Validation of the Turkish Version of the Catheterization Risk Score for Pediatrics
Pediatrics,cardiac catheterization,adverse event,risk score,validation
- 28 November 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (12) , 864-871
Open AccessValidation of the Turkish Version of the Catheterization Risk Score for Pediatrics
Pediatrics,cardiac catheterization,adverse event,risk score,validation
- Open Access
- 20 August 2022
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 20 (1) , 1-6
A retrospective comparative analysis of factors affecting the decision and outcome of initial intravenous immunoglobulin alone or intravenous immunoglobulin plus methylprednisolone use in children with the multisystem inflammatory syndrome
Background: For children with the multisystem inflammatory syndrome(MIS-C), intravenous immunoglobulins (IVIG) with or without methylprednisolone are the most effective treatment. In this study, IVIG combined with methylprednisolone was compared to IVIG used alone in children with MIS-C.Methods: This retrospective cohort study was carried out between April 1, 2020, and November 1, 2021. This study covered all children with MIS-C. According to whether they received IVIG alone or IVIG with methylprednisolone as an initial treatment for MIS-C, the patients were split into two groups. The IVIG dosage for the patients in group I was 2 gr/kg, whereas the IVIG dosage for the patients in group II was 2 gr/kg + 2 mg/kg/day of methylprednisolone. These two groups were contrasted in terms of the frequency of fever, length of hospital stay, and admission to the pediatric intensive care unit.Results: The study comprised 91 patients who were diagnosed with MIS-C and were under the age of 18. 42 (46.2%) of these patients were in the IVIG alone group (group I), and 49 (53.8%) were in the IVIG + methylprednisolone group (group II). Patients in group II had a severe MIS-C ratio of 36.7%, which was substantially greater than the rate of severe MIS-C patients in group I (9.5%) (p 0.01). When compared to group I (9.5%), the rate of hypotension was considerably higher in group II (30.6%) (p = 0.014). Additionally, patients in group II had considerably higher mean serum levels of C-reactive protein. The incidence of fever recurrence was 26.5% in group II and 33.3% in group I, however the difference was not statistically significant (p > 0.05).Conclusions: The choice of treatment for patients with MIS-C should be based on an individual evaluation. In MIS-C children with hypotension and/or with an indication for a pediatric intensive care unit, a combination of IVIG and methylprednisolone may be administered. For the treatment modalities of children with MIS-C, however, randomized double-blind studies are necessary.
- 20 August 2022
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 20 (1) , 1-6
Open AccessA retrospective comparative analysis of factors affecting the decision and outcome of initial intravenous immunoglobulin alone or intravenous immunoglobulin plus methylprednisolone use in children with the multisystem inflammatory syndrome
Background: For children with the multisystem inflammatory syndrome(MIS-C), intravenous immunoglobulins (IVIG) with or without methylprednisolone are the most effective treatment. In this study, IVIG combined with methylprednisolone was compared to IVIG used alone in children with MIS-C.Methods: This retrospective cohort study was carried out between April 1, 2020, and November 1, 2021. This study covered all children with MIS-C. According to whether they received IVIG alone or IVIG with methylprednisolone as an initial treatment for MIS-C, the patients were split into two groups. The IVIG dosage for the patients in group I was 2 gr/kg, whereas the IVIG dosage for the patients in group II was 2 gr/kg + 2 mg/kg/day of methylprednisolone. These two groups were contrasted in terms of the frequency of fever, length of hospital stay, and admission to the pediatric intensive care unit.Results: The study comprised 91 patients who were diagnosed with MIS-C and were under the age of 18. 42 (46.2%) of these patients were in the IVIG alone group (group I), and 49 (53.8%) were in the IVIG + methylprednisolone group (group II). Patients in group II had a severe MIS-C ratio of 36.7%, which was substantially greater than the rate of severe MIS-C patients in group I (9.5%) (p 0.01). When compared to group I (9.5%), the rate of hypotension was considerably higher in group II (30.6%) (p = 0.014). Additionally, patients in group II had considerably higher mean serum levels of C-reactive protein. The incidence of fever recurrence was 26.5% in group II and 33.3% in group I, however the difference was not statistically significant (p > 0.05).Conclusions: The choice of treatment for patients with MIS-C should be based on an individual evaluation. In MIS-C children with hypotension and/or with an indication for a pediatric intensive care unit, a combination of IVIG and methylprednisolone may be administered. For the treatment modalities of children with MIS-C, however, randomized double-blind studies are necessary.